Published on

Medicine – Syphilis Serology: Interpretation of VDRL, TPHA and FTA-ABS Tests at Different Stages of Syphilis

1. Introduction to Syphilis Serology

Syphilis is a sexually transmitted infection caused by Treponema pallidum, a thin, spiral-shaped bacterium belonging to the spirochaete group.

The disease progresses through several clinical stages, including primary syphilis, secondary syphilis, latent syphilis and tertiary syphilis. Congenital syphilis occurs when the organism is transmitted from an infected pregnant individual to the fetus during pregnancy.

Laboratory diagnosis relies primarily on serological tests that detect antibodies associated with Treponema pallidum infection. These tests are divided into two major categories: non-treponemal tests and treponemal tests.

The three tests highlighted in the original table are the Venereal Disease Research Laboratory (VDRL) test, Treponema pallidum haemagglutination assay (TPHA) and fluorescent treponemal antibody absorption (FTA-ABS) test.

Their results vary according to the stage of infection, the timing of antibody development and whether the patient has previously received treatment.

An important principle is that no single serological test can reliably determine the stage of syphilis or distinguish active infection from previously treated infection in every patient.

2. Classification of Syphilis Serological Tests

Syphilis serological tests are classified into non-treponemal and treponemal tests.

Non-treponemal tests, such as VDRL and rapid plasma reagin (RPR), detect antibodies directed against lipid antigens, including cardiolipin, that arise during infection and tissue injury. These tests are particularly useful for assessing disease activity and monitoring response to treatment.

Treponemal tests, such as TPHA and FTA-ABS, detect antibodies directed against antigens associated with Treponema pallidum. They are primarily used to provide evidence of current or previous infection.

Treponemal tests often remain positive for many years, sometimes throughout life, even after successful treatment.

Modern laboratories may also use automated treponemal enzyme immunoassays or chemiluminescence immunoassays for screening.

Non-Treponemal Serological Tests

3. Venereal Disease Research Laboratory Test (VDRL)

The VDRL test is a non-treponemal serological investigation used in the diagnosis and monitoring of syphilis.

It detects antibodies that react with a laboratory antigen mixture containing cardiolipin, lecithin and cholesterol.

These antibodies are not directed specifically against Treponema pallidum. Instead, they are associated with tissue damage and the host immune response during infection.

VDRL may become positive during primary syphilis, but it can remain negative during the earliest stages because sufficient antibodies have not yet developed.

Its sensitivity is generally high during secondary syphilis, when the antibody response is more pronounced.

4. Interpretation of VDRL Results

A positive VDRL test supports the possibility of syphilis but does not independently establish the diagnosis because false-positive reactions can occur.

VDRL results may be reported as reactive or non-reactive and, when reactive, as quantitative antibody titres.

The titre is determined by serially diluting the patient’s serum until the reaction is no longer detectable.

For example, a patient may have a VDRL titre of 1:32 before treatment and 1:8 during follow-up.

This represents a fourfold decline in titre, equivalent to a decrease of two serial dilutions.

Such changes are important when assessing treatment response, although the expected timing depends on the stage of infection and clinical circumstances.

5. Rapid Plasma Reagin Test (RPR)

RPR is another commonly used non-treponemal test.

Like VDRL, it detects antibodies against cardiolipin-containing antigens rather than antibodies specific to Treponema pallidum.

RPR is widely used for screening and monitoring treatment response.

RPR and VDRL titres are not directly interchangeable because their numerical values may differ.

For follow-up, the same type of non-treponemal test should ideally be used consistently, preferably in the same laboratory.

6. False-Positive Non-Treponemal Tests

Non-treponemal tests may occasionally produce positive results in individuals without syphilis.

Potential associations include pregnancy, autoimmune diseases such as systemic lupus erythematosus, certain acute infections and other inflammatory conditions.

These are referred to as biological false-positive reactions.

For this reason, a reactive VDRL or RPR result generally requires interpretation alongside a treponemal test.

A positive non-treponemal test combined with a positive treponemal test provides stronger evidence of current or previous syphilis infection.

Treponemal Serological Tests

7. Treponema Pallidum Haemagglutination Assay (TPHA)

TPHA is a treponemal serological test that detects antibodies directed against Treponema pallidum antigens.

It is based on a haemagglutination reaction in which particles coated with treponemal antigens react with antibodies present in the patient’s serum.

A positive TPHA result indicates exposure to Treponema pallidum, although it does not necessarily indicate active infection.

TPHA may be negative during very early primary syphilis because the immune response has not yet developed sufficiently.

As infection progresses, the test usually becomes reactive.

After successful treatment, TPHA commonly remains positive for many years or throughout life.

8. Clinical Significance of TPHA

TPHA is useful for confirming evidence of treponemal infection when a non-treponemal screening test is reactive.

However, a positive TPHA result cannot reliably distinguish untreated syphilis from previously treated infection.

For example, a patient who received adequate treatment several years earlier may have a negative VDRL but persistently positive TPHA.

This pattern does not automatically indicate treatment failure or reinfection.

The patient’s treatment history, symptoms, examination findings and previous serological results must be considered.

9. Fluorescent Treponemal Antibody Absorption Test (FTA-ABS)

FTA-ABS is a treponemal test that detects antibodies directed against Treponema pallidum.

It uses an indirect immunofluorescence technique.

The patient’s serum is exposed to treponemal antigens, and fluorescently labelled antibodies are used to identify binding.

FTA-ABS may become reactive relatively early in infection, sometimes before other traditional serological tests.

However, FTA-ABS is not universally positive in early primary syphilis, and a negative result does not exclude infection during the earliest stages.

Modern automated treponemal immunoassays have largely replaced FTA-ABS in many laboratories.

10. Clinical Significance of FTA-ABS

A positive FTA-ABS test provides evidence of treponemal antibody formation.

Like TPHA, FTA-ABS often remains reactive after successful treatment.

Therefore, it is not generally used to monitor the effectiveness of therapy.

A positive FTA-ABS result must be interpreted together with the patient’s clinical history and other laboratory findings.

In particular, a positive treponemal test with a negative VDRL may reflect previously treated infection, very early infection, late untreated infection or occasionally a false-positive treponemal result.

Syphilis Serology at Different Stages

11. Primary Syphilis

Primary syphilis is the earliest symptomatic stage of infection and usually develops after an incubation period of approximately three weeks, although the interval can vary.

The classical clinical manifestation is a chancre, which is typically a painless ulcer at the site of inoculation.

Regional lymphadenopathy may also occur.

During this stage, the immune system begins producing antibodies against Treponema pallidum and associated antigens.

However, serological tests may remain negative early in the disease because antibody concentrations have not yet reached detectable levels.

12. VDRL in Primary Syphilis

The original table indicates that VDRL may be positive or negative during primary syphilis.

This is correct.

During early primary infection, VDRL may be non-reactive because the antibody response is still developing.

As the infection progresses, the likelihood of a positive VDRL increases.

Therefore, a negative VDRL result does not exclude primary syphilis when a patient has a characteristic chancre or a recent high-risk exposure.

If clinical suspicion remains high, repeat serological testing after an appropriate interval or direct testing of a lesion may be necessary.

13. TPHA in Primary Syphilis

The original table indicates that TPHA is negative during primary syphilis.

This requires clarification.

TPHA may be negative during very early primary syphilis, but it can become positive later in the primary stage.

The timing depends on the development of the patient’s antibody response and the sensitivity of the test.

Therefore, TPHA should not be considered universally negative throughout primary syphilis.

A negative TPHA result in a patient with a typical chancre does not reliably exclude early infection.

14. FTA-ABS in Primary Syphilis

The original table indicates that FTA-ABS is positive during primary syphilis.

FTA-ABS can become reactive early in infection and may detect antibodies before some other traditional tests.

However, it is not invariably positive in the earliest stage.

A patient with a newly developed chancre may still have negative serological results.

Therefore, early primary syphilis can be seronegative on all three tests.

Clinical assessment and direct detection methods, where available, remain important when early infection is suspected.

15. Late Primary Syphilis

Late primary syphilis refers to the later portion of the primary stage, when the chancre may still be present or beginning to heal.

By this time, the immune system has generally produced a more substantial antibody response.

The original table shows VDRL as positive, TPHA as variably positive and FTA-ABS as positive.

This broadly reflects increasing test sensitivity as infection progresses.

However, antibody development varies between patients, and no specific combination of results is guaranteed.

In most patients, both non-treponemal and treponemal tests become reactive as primary infection advances.

16. Secondary Syphilis

Secondary syphilis occurs after dissemination of Treponema pallidum throughout the body.

It may develop several weeks after the appearance of the primary chancre, although primary and secondary manifestations can overlap.

Common clinical features include a generalised rash, often involving the palms and soles, mucous patches, condylomata lata and generalised lymphadenopathy.

Systemic symptoms such as fever, malaise and weight loss may also occur.

Secondary syphilis is associated with a strong antibody response, making serological tests highly sensitive during this stage.

17. VDRL in Secondary Syphilis

VDRL is usually reactive during secondary syphilis.

Non-treponemal antibody titres are often relatively high because of the pronounced immune response.

Therefore, VDRL and RPR are particularly sensitive during this stage.

However, an important laboratory phenomenon called the prozone effect can occasionally cause a falsely non-reactive result.

This occurs when extremely high antibody concentrations interfere with the formation of visible antigen-antibody complexes.

Diluting the serum can resolve this problem.

The prozone effect should be considered when clinical findings strongly suggest secondary syphilis despite a negative non-treponemal test.

18. TPHA and FTA-ABS in Secondary Syphilis

Both TPHA and FTA-ABS are generally positive during secondary syphilis.

This reflects the development of a substantial antibody response against treponemal antigens.

The combination of a reactive non-treponemal test and a reactive treponemal test strongly supports syphilis in a patient with compatible clinical manifestations.

However, treponemal test positivity does not independently determine whether the infection is newly acquired or previously treated.

Clinical staging still depends on symptoms, examination findings, exposure history and previous test results.

Latent Syphilis

19. Introduction to Latent Syphilis

Latent syphilis is characterised by positive serological evidence of infection without clinical signs or symptoms of primary, secondary or tertiary syphilis.

The patient may appear entirely healthy despite persistent infection.

Latent syphilis is classified as early latent or late latent according to the estimated duration of infection.

Under commonly used CDC criteria, early latent syphilis refers to infection acquired within the preceding year, while late latent syphilis refers to infection of longer duration.

When the duration cannot be established, the condition is classified as latent syphilis of unknown duration.

20. VDRL in Latent Syphilis

The original table indicates that VDRL is positive during latent syphilis.

Although VDRL may remain positive, it can also become non-reactive during late latent infection, particularly when antibody titres decline.

Non-treponemal titres are often lower during late latent syphilis than during secondary syphilis.

Therefore, a negative VDRL does not reliably exclude late latent syphilis.

The interpretation of a negative VDRL with a positive treponemal test requires assessment of previous treatment and exposure history.

21. TPHA and FTA-ABS in Latent Syphilis

TPHA and FTA-ABS generally remain reactive during latent syphilis.

Treponemal antibodies may persist even when clinical symptoms are absent and non-treponemal titres have declined.

This makes treponemal tests useful for identifying evidence of previous exposure.

However, persistent positivity does not necessarily indicate that viable organisms remain after adequate treatment.

A positive treponemal test cannot independently distinguish untreated latent syphilis from previously treated infection.

Tertiary Syphilis

22. Introduction to Tertiary Syphilis

Tertiary syphilis refers to late clinical manifestations that may develop years or decades after untreated infection.

Important manifestations include gummatous syphilis and cardiovascular syphilis, particularly syphilitic aortitis.

Neurosyphilis can occur at any stage of infection and is not restricted to tertiary disease.

The original table groups secondary and tertiary syphilis together, but their serological patterns are not identical.

Secondary syphilis usually produces a strong non-treponemal antibody response, whereas non-treponemal titres may decline during late disease.

23. VDRL in Tertiary Syphilis

VDRL may be positive in tertiary syphilis, but it is not universally reactive.

Some patients with longstanding infection have low or non-reactive non-treponemal titres.

Therefore, the original table’s indication that VDRL is always positive during tertiary syphilis is an oversimplification.

A negative VDRL does not completely exclude late syphilis.

Clinical findings, treponemal tests and appropriate investigations are needed to establish the diagnosis.

24. TPHA and FTA-ABS in Tertiary Syphilis

Treponemal tests such as TPHA and FTA-ABS generally remain positive during tertiary syphilis.

This reflects the persistence of treponemal antibodies following infection.

The presence of a positive treponemal test with compatible late clinical manifestations supports the diagnosis.

However, because treponemal antibodies can remain positive after successful treatment, the result must be interpreted alongside the patient’s history and clinical findings.

25. Late or Quaternary Syphilis

The original table includes a category called late-quaternary syphilis.

Quaternary syphilis is not a standard stage in modern clinical classification.

Contemporary classifications generally recognise primary, secondary, latent and tertiary syphilis, while neurosyphilis, ocular syphilis and otosyphilis may occur at different stages.

The term quaternary syphilis has occasionally appeared in older literature but is not routinely used in modern diagnostic or treatment guidelines.

For examination purposes, late disease should generally be discussed under late latent syphilis, tertiary syphilis or the relevant organ-specific manifestation.

Serological results in longstanding infection may show persistently positive treponemal tests with variable non-treponemal reactivity.

Serology After Treatment

26. Treated Syphilis

Following successful treatment of syphilis, non-treponemal antibody titres generally decline.

VDRL or RPR may eventually become non-reactive, particularly when treatment is administered during early infection.

However, some patients retain low-level reactive non-treponemal titres despite adequate treatment.

This is sometimes described as the serofast state.

Treponemal tests such as TPHA and FTA-ABS frequently remain positive for many years or throughout life.

Therefore, the original table’s pattern of negative VDRL with positive TPHA and FTA-ABS is a possible outcome of treated syphilis, but it is not universal.

27. Monitoring Response to Treatment

The effectiveness of syphilis treatment is primarily monitored using quantitative non-treponemal titres.

A fourfold decline in VDRL or RPR titre is an important indicator of serological response.

For example, a decrease from 1:64 to 1:16 represents a fourfold decline.

The expected rate of decline depends on the stage of infection, the initial titre, previous treatment history and patient-specific factors.

A sustained fourfold increase in titre may indicate reinfection or treatment failure and requires further clinical evaluation.

Treponemal tests are generally not useful for monitoring treatment response because they often remain reactive despite successful therapy.

28. Serofast State

The serofast state refers to persistent low-level non-treponemal test reactivity following adequate syphilis treatment.

For example, a patient may have a VDRL titre of 1:2 or 1:4 that remains stable despite appropriate therapy.

This does not necessarily indicate active infection or treatment failure.

The interpretation depends on the patient’s treatment history, previous titres, risk of reinfection and clinical findings.

Repeated treatment is not automatically required solely because a low non-treponemal titre remains reactive.

Congenital Syphilis

29. Introduction to Congenital Syphilis

Congenital syphilis occurs when Treponema pallidum is transmitted from an infected pregnant individual to the fetus through the placenta.

Transmission may occur during different stages of maternal infection, with particularly high risk during early untreated syphilis.

Congenital syphilis can cause miscarriage, stillbirth, neonatal death or significant disease in surviving infants.

Clinical manifestations may include hepatosplenomegaly, rash, rhinitis, bone abnormalities, anaemia and neurological involvement.

Early maternal screening and appropriate penicillin treatment are essential for prevention.

30. VDRL in Congenital Syphilis

VDRL or RPR testing is important in the evaluation of suspected congenital syphilis.

However, a positive test in a newborn does not independently establish congenital infection.

Maternal non-treponemal antibodies can cross the placenta and produce a reactive test in an uninfected infant.

Therefore, the infant’s quantitative non-treponemal titre should be compared with the maternal titre obtained using the same test method.

An infant titre at least fourfold higher than the maternal titre strongly supports congenital syphilis, although a lower titre does not exclude infection.

31. TPHA and FTA-ABS in Congenital Syphilis

Treponemal tests may be positive in newborn infants because maternal IgG antibodies cross the placenta.

Consequently, positive TPHA or FTA-ABS results in a newborn do not necessarily indicate congenital infection.

This is an important limitation of the original table, which shows all three tests as positive in congenital syphilis.

Maternal treponemal antibodies may persist in the infant for many months.

Diagnosis requires consideration of maternal treatment, maternal and infant non-treponemal titres, clinical examination and other investigations.

Treponemal tests are therefore not routinely used to assess treatment response in infants with congenital syphilis.

Practical Interpretation of Syphilis Serology

32. Positive VDRL and Positive TPHA

A positive VDRL combined with a positive TPHA provides evidence supporting current or previous syphilis infection.

In a patient with compatible symptoms and no previous treatment, this pattern strongly suggests active infection.

However, both tests may remain reactive after treatment.

Therefore, the result must be interpreted in the context of clinical findings, treatment history and previous titres.

A quantitative non-treponemal titre is important for establishing a baseline before treatment.

33. Negative VDRL and Positive TPHA

A negative VDRL with a positive TPHA may occur in several circumstances.

One possibility is previously treated syphilis, where the non-treponemal test has become non-reactive but treponemal antibodies persist.

Another possibility is very early infection before the non-treponemal antibody response becomes detectable.

Late untreated syphilis may also produce this pattern.

Occasionally, a positive treponemal result may be false-positive.

Further evaluation may include a second treponemal assay using a different method, review of previous treatment and repeat testing when recent infection is suspected.

34. Positive VDRL and Negative TPHA

A positive VDRL with a negative TPHA may represent a biological false-positive non-treponemal reaction.

Potential causes include autoimmune disease, pregnancy and certain infections.

However, early syphilis remains a consideration when exposure history or clinical findings are strongly suggestive.

Repeat testing or additional confirmatory testing may be necessary.

The diagnosis should not be based on the VDRL result alone.

35. Negative VDRL and Negative TPHA

Negative results on both non-treponemal and treponemal tests generally make established syphilis less likely.

However, very early primary syphilis may produce negative results because antibodies have not yet developed.

Therefore, negative serology does not completely exclude recent infection.

If a patient has a characteristic chancre or a credible recent exposure, repeat serological testing and direct lesion testing, where available, should be considered.

Syphilis Serology by Disease Stage – Note Form

36. Primary Syphilis

During primary syphilis, VDRL may be positive or negative, depending on how long the infection has been present.

TPHA may also be negative early and become positive as the antibody response develops.

FTA-ABS may become positive relatively early but is not always reactive at the beginning of primary infection.

Therefore, all three tests may be negative during very early primary syphilis.

37. Late Primary Syphilis

During late primary syphilis, VDRL is more likely to be positive because non-treponemal antibodies have increased.

TPHA and FTA-ABS are also increasingly likely to be reactive.

Most patients develop positive serological tests as the primary stage progresses.

However, individual variation in antibody development remains possible.

38. Secondary Syphilis

During secondary syphilis, VDRL is usually positive and often demonstrates a relatively high titre.

TPHA is generally positive.

FTA-ABS is also generally positive.

Secondary syphilis is therefore associated with high sensitivity of both non-treponemal and treponemal serological tests.

A rare prozone effect can produce a falsely negative non-treponemal result.

39. Latent Syphilis

During latent syphilis, TPHA and FTA-ABS generally remain positive.

VDRL may be positive, particularly in early latent infection, but titres may decline during late latent disease.

Some patients with late latent syphilis have non-reactive VDRL results.

Therefore, the pattern depends on the duration of infection and previous treatment history.

40. Tertiary Syphilis

During tertiary syphilis, TPHA and FTA-ABS usually remain positive.

VDRL may be positive but can be non-reactive in some patients with longstanding infection.

The diagnosis depends on compatible clinical findings and supporting laboratory evidence.

Neurosyphilis may occur at any stage and requires separate clinical assessment.

41. Treated Syphilis

Following successful treatment, VDRL or RPR titres generally decline.

Some patients eventually become non-reactive, while others remain serofast with persistent low titres.

TPHA and FTA-ABS commonly remain positive for many years or throughout life.

Therefore, positive treponemal tests do not automatically indicate active disease after treatment.

42. Congenital Syphilis

In congenital syphilis, VDRL or RPR may be reactive.

However, maternal antibodies can produce positive serological tests in an infant who is not infected.

TPHA and FTA-ABS may also be positive because of transplacental transfer of maternal IgG.

Diagnosis therefore requires comparison of maternal and infant non-treponemal titres, maternal treatment history and appropriate clinical evaluation.

43. Important Corrections to the Original Table

The original table provides a simplified overview of syphilis serology, but several details require correction.

Primary syphilis: VDRL, TPHA and FTA-ABS can all be negative during very early infection. TPHA is not necessarily negative throughout the entire primary stage.

Late primary syphilis: All three tests become increasingly likely to be positive as antibody production increases.

Secondary syphilis: VDRL, TPHA and FTA-ABS are generally positive, although rare exceptions such as the prozone effect can occur.

Tertiary syphilis: Treponemal tests usually remain positive, but VDRL is not always reactive.

Late-quaternary syphilis: This is not a standard modern clinical classification.

Latent syphilis: Treponemal tests generally remain positive, whereas VDRL may become negative in late infection.

Treated syphilis: VDRL titres usually decline but do not always become negative. Treponemal tests often remain positive.

Congenital syphilis: Positive serology in a newborn may reflect passively transferred maternal antibodies rather than true congenital infection.

44. Important Examination Associations

VDRL and RPR are non-treponemal tests used for screening and monitoring treatment response.

TPHA and FTA-ABS are treponemal tests that provide evidence of current or previous infection.

Primary syphilis may have negative serology during the early antibody window period.

Secondary syphilis usually produces strongly reactive non-treponemal and treponemal tests.

Latent syphilis may have no symptoms despite positive serology.

Tertiary syphilis may have positive treponemal tests with low or negative non-treponemal titres.

Previously treated syphilis may demonstrate negative VDRL with persistently positive TPHA or FTA-ABS.

Congenital syphilis cannot be diagnosed from positive neonatal treponemal tests alone because maternal antibodies can cross the placenta.

Key Clinical Pattern

The most important distinction in syphilis serology is between non-treponemal tests, which are useful for monitoring disease activity and treatment response, and treponemal tests, which often remain positive after infection has been treated.

VDRL / RPR → Non-treponemal → Quantitative titres → Monitor treatment response.

TPHA → Treponemal → Evidence of current or previous infection → Often remains positive after treatment.

FTA-ABS → Treponemal → May become reactive early → Often remains positive after treatment.

Very early primary syphilis → All serological tests may be negative.

Secondary syphilis → VDRL positive, TPHA positive, FTA-ABS positive in most patients.

Late latent or tertiary syphilis → Treponemal tests usually positive, VDRL variable.

Treated syphilis → VDRL titre declines, but TPHA and FTA-ABS often remain positive.

Congenital syphilis → Interpret neonatal serology with maternal titres and treatment history.

For examinations, remember that VDRL and RPR are primarily used to assess treatment response, while TPHA and FTA-ABS provide evidence of treponemal infection but cannot reliably distinguish active disease from previously treated syphilis.


Image description
0 Comments